Search filters

List of works by Andrew M. Wardley

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

scientific article published in January 2007

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

scientific article published on 06 June 2019

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

scientific article published on 18 December 2018

A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition

scientific article published on 17 November 2015

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

scientific article published on 13 September 2007

A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre

scientific article published on 10 October 2007

A quantitative histometric murine in vivo model of radiation-induced oral mucositis.

scientific article

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

scientific article published on 7 May 2013

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

scientific article published on 30 April 2015

Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, c ⬇️

article

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

scientific article published on 4 May 2017

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

scientific article

Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.

scientific article published on 5 April 2018

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

scientific article

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

scientific article published on 20 October 2011

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

scientific article published on 13 February 2013

Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer.

scientific article published on January 2006

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

scientific article published on 30 April 2018

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

scientific article published on 12 March 2019

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

scientific article published on 28 January 2010

Does HER2 overexpression affect response to endocrine therapy in advanced cancer?

scientific article published on 01 February 2006

Effective oral chemotherapy for breast cancer: pillars of strength.

scientific article

Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial

scientific article published on 16 November 2009

Emerging targeted combinations in the management of breast cancer

scientific article published on 13 August 2013

Erratum to: Patient-Derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.

scientific article published on 4 November 2016

Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer

scientific article published on 2 September 2010

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis

scientific article published on 01 July 1996

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

article

Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme

scientific article

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

scientific article published on 29 July 2013

Genomic profile of advanced breast cancer in circulating tumour DNA

scientific article published on 23 April 2021

Impact of skeletal complications on patients' quality of life, mobility, and functional independence

scientific article published on 08 April 2008

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated

scientific article published on 21 December 2009

Letrozole: advancing hormone therapy in breast cancer

scientific article published in November 2012

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

scientific article published in February 2009

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

scientific article published on 9 June 2005

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

scientific article published in January 2017

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

scientific article published on 01 June 2019

Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis

scientific article published on 28 September 2016

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

scientific article

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients

scientific article published on 15 March 2012

Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.

scientific article

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

scientific article published on 14 February 2007

Preliminary Phase II Data Suggest That Entinostat (SNDX275), a Class 1 Selective Histone Deacetylase Inhibitor (HDACi), May Resensitize Breast Cancer Patients Progressing on Aromataste Inhibitor (AI) Therapy to Their AI Therapy

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

scientific article published on 01 May 2019

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

scientific article published on 22 October 2018

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

scientific article published on 3 June 2013

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

scientific article published on 28 December 2009

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer

scientific article published on 18 July 2011

Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

scientific article published in December 2009

Second-line treatment of postmenopausal women with advanced breast carcinoma

scientific article

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

scientific article published on May 2009

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

scientific article published on 01 August 2020

Symptoms of endocrine treatment and outcome in the BIG 1-98 study.

scientific article published on 05 December 2013

TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.

scientific article

The need for advanced breast cancer treatment guidelines: results of an internet-based survey

scientific article

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone ⬇️

scientific article published on September 1, 1998

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature

scientific article published on 10 November 2020

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

scientific article published on 28 September 2009

Trastuzumab-associated cardiac events in the Persephone trial

scientific article published on 22 November 2016

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

scientific article

Understanding the BIG results: Insights from the BIG 1-98 trial analyses.

scientific article published on December 2008

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

scientific article

Paulina is supported by:

About Paulina

Help